Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants

AIDS

Volumn 17, Issue 14, 2003, Pages 2053-2061

  Le Chenadec, Jérôme ^a   Mayaux, Marie Jeanne ^a   Guihenneuc Jouyaux, Chantal ^b   Blanche, Stéphane ^c  

^a BICÊTRE HOSPITAL   (France)

^b CNRS   (France)

^c Service d'Immunologie et Hématologie Pédiatrique   (France)

Author keywords

Hematopoiesis toxicity; Pregnancy; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; HEMOGLOBIN; LAMIVUDINE; NUCLEOSIDE ANALOG; ZIDOVUDINE;

AGE; ARTICLE; BLOOD TOXICITY; CELL COUNT; CELL LINEAGE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; EVOLUTION; FEMALE; GEOGRAPHY; HEMATOLOGICAL PARAMETERS; HEMATOPOIESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MODEL; MONOTHERAPY; MOTHER; MULTIVARIATE ANALYSIS; NEUTROPHIL; NEWBORN; NONLINEAR SYSTEM; PERINATAL CARE; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SERODIAGNOSIS; THROMBOCYTE;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HEMATOPOIESIS; HEMOGLOBINS; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LYMPHOCYTE SUBSETS; MATERNAL-FETAL EXCHANGE; NEUTROPHILS; PLATELET COUNT; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TIME FACTORS; ZIDOVUDINE;

EID: 0142062006     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200309260-00006     Document Type: Article

References (30)

1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type-1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180.
2. Taylor GP, Low-Beer N. Antiretroviral therapy in pregnancy. A focus on safety. Drug Safety 2001; 24:683-702.
3. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection study group. N Engl J Med 2000; 343: 759-766.
4. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 0176 Study. AIDS 1998; 12:1805-1813.
5. Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281:151-157.
6. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-1089.
7. Landreau-Mascaro A, Barret B, Mayaux MJ, Tardieu M, Blanche S. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002; 359:583-584.
8. Nielsen SD, Jeppesen DL, Kolte L, Clark DR, Sorensen TU, Dreves AM et al. Impaired progenitor cell function in HIV negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts. Blood 2001; 98:398-404.
9. Blanche S, Rouzioux C, Moscato ML, Veber F, Mayaux MJ, Jacome C, et al. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. HIV Infection in Newborns French Collaborative Study Group. N Engl J Med 1989; 320:1643-1648.
10. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Amer Stat Assoc 1979; 74:829-836.
11. Wold S. Spline functions in data analysis. Technometrics 1974; 16:1-11.
12. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38:963-974.
13. Hastie TJ, Tibshirani RJ. Generalized Additive Models. Monographs on Statistics and Applied Probability, London: Chapman & Hall: 1990.
14. Shi M, Weiss RE, Taylor JMG. An analysis of pediatric CD4 counts for acquired immune deficiency syndrom using flexible random curves. Appl Stat 2001; 50:375-387.
15. Harrell FE. Regression Modeling Strategies. Springer Series in Statistics. Berlin: Springer; 2001.
16. Read WW, Diehl LF. Leukopenia, neutropenia and reduced hemoglobin levels in healthy American blacks. Arch Intern Med 1991; 151:501-505.
17. Lisse IM, Aaby P, Whittle H, Jensen H, Engelmann M, Christensen LB. T-lymphocyte subsets in West African children: impact of age, sex, and season. J Pediatr 1997; 130:77-85.
18. Rudy BJ, Crowley-Nowick PA, Douglas SD. Immunology and the REACH study: HIV immunology and preliminary findings. J Adolesc Health 2001; 295:39-48.
19. Stevens RF, Alexander MK. A sex difference in the platelet count. Br J Haematol 1977; 37:295-300.
20. Hambleton J. Hematologic complications of HIV infection. Oncology 1996; 10:671-680.
21. Lipshultz SE, Easley KA, Kaplan S, Starc TJ, Bricker JT, Lai WW, et al. Cardiovascular status of infants and children of women infected with HIV-1 (p2c2 HIV): a cohort study. Lancet 2002; in press.
22. Gribaldo L, Malerba I, Collotta A, Casati S, Pessina A. Inhibition of CFU-E/BFU-E by 3′-azido-3′-deoxythymidine, chlorpropamide, and protoporphirin IX Zinc (II): A comparison between direct exposure of progenitor cells and long-term exposure of bone marrow cultures. Toxicol Sci 2000; 58:96-101.
23. Fowler DA, Xi M-Y, Sommadossi J-P. Protection and rescue from 2′, 3′-dideoxypyrimidine nucleotide analog toxicity by hemin in human bone marrow progenitor cells. Antimicrob. Agents Chemother 1996; 40:191-195.
24. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nature Med 1995; 5:417-422.
25. Wutzler P, Thust R. Genetic risks of antiviral nucleoside analogues - a survey. Antiviral Res 2001; 49:55-74.
26. Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St Claire ME, Poirier MC. et al. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 2002; 29:323-329.
27. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Baker R, Stek AM, et al. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant woman, and cord blood from infants exposed in utero. AIDS 1999; 13:819-825.
28. Sommadossi J.P, Carlisle R, Zhou Z. Cellular pharmacology of 3′azido 3′deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol Pharmacol 1989; 36:9-14.
29. Spiga MG, Weidner DA, Trentesaux C, LeBoeuf RD, Sommadossi JP. Inhibition of β globin gene expression by 3′ azido 3′ deoxythymidine in human erythroïd progenitor cells. Antiviral Res 1999; 44:167-177.
30. Chitnis S, Mondal D, Agrawal KC. Zidovudine (AZT) treatment suppresses granulocyte-monocyte colony factor receptor type alpha (GM CSFRa) gene expression in murine bone marrow cells. Life Sci 2002; 71:967-978.